Cemiplimab
Libtayo (cemiplimab) is an antibody pharmaceutical. Cemiplimab was first approved as Libtayo on 2018-09-28. It is used to treat squamous cell carcinoma in the USA. It has been approved in Europe to treat squamous cell neoplasms. The pharmaceutical is active against programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| libtayo | Biologic Licensing Application | 2024-06-05 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9119 | Injection, cemiplimab-rwlc, 1 mg |
Clinical
Clinical Trials
178 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 8 | 15 | 4 | — | 2 | 27 |
| Squamous cell carcinoma | D002294 | — | — | 7 | 15 | 2 | — | 3 | 26 |
| Non-small-cell lung carcinoma | D002289 | — | — | 5 | 18 | 6 | — | 2 | 24 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 10 | 6 | — | 2 | 17 |
| Melanoma | D008545 | — | — | 3 | 9 | 4 | — | — | 13 |
| Squamous cell neoplasms | D018307 | — | — | 2 | 1 | 1 | — | — | 4 |
| Uterine cervical neoplasms | D002583 | — | — | 1 | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 12 | 8 | — | — | — | 15 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 9 | — | — | — | 12 |
| Prostatic neoplasms | D011471 | — | C61 | 6 | 5 | — | — | — | 7 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 5 | 5 | — | — | — | 6 |
| Basal cell carcinoma | D002280 | — | — | 1 | 2 | — | — | 1 | 4 |
| Basal cell neoplasms | D018295 | — | — | 1 | 2 | — | — | 1 | 4 |
| Recurrence | D012008 | — | — | 3 | 2 | — | — | — | 4 |
| Head and neck neoplasms | D006258 | — | — | 3 | 2 | — | — | — | 3 |
| Fallopian tube neoplasms | D005185 | — | — | 3 | 2 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 1 | 3 | — | — | — | 3 |
Show 35 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Anaplastic thyroid carcinoma | D065646 | — | — | 1 | — | — | — | — | 1 |
| Thyroid diseases | D013959 | — | E00-E07 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cemiplimab |
| INN | cemiplimab |
| Description | Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >8GY5:A,H|heavy chain
EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLY
LQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH
>8GY5:B,L|light chain
DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQP
EDFATYYCQQSSNTPFTFGPGTVVDFRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 7WVM, 8GY5 |
| CAS-ID | — |
| RxCUI | 2058826 |
| ChEMBL ID | CHEMBL4297723 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14707 |
| UNII ID | 6QVL057INT (ChemIDplus, GSRS) |
Target
Agency Approved
PDCD1
PDCD1
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Libtayo – Regeneron Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,485 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,164 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use